Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H30O2 |
Molecular Weight | 314.4617 |
Optical Activity | ( - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
InChI
InChIKey=QHMBSVQNZZTUGM-ZWKOTPCHSA-N
InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1
DescriptionCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24854329 | https://www.gwpharm.com/products-pipeline
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24854329 | https://www.gwpharm.com/products-pipeline
Cannabidiol is the major nonpsychoactive ingredient in cannabis. Cannabidiol demonstrates a range of effects that may be therapeutically useful, including anti-seizure, antioxidant, neuroprotective, anti-inflammatory, analgesic, anti-tumor, anti-psychotic, and anti-anxiety properties. Exact mechanism of action of cannabidiol is not known, but may include effects on the orphan G-protein-coupled receptor GPR55; the transient receptor potential of vanilloid type-1 channel; the 5-HT1a receptor; and the α3 glycine receptors. GW Pharmaceuticals successfully developed the world’s first prescription medicine derived from the cannabis plant, Sativex® (buccal spray containing delta-9-tetrahydrocannabinol and cannabidiol) now approved in over 29 countries outside of the United States for the treatment of spasticity due to Multiple Sclerosis. GW Pharmaceuticals is developing Epidiolex® (a liquid formulation of pure plant-derived cannabidiol) for certain rare and severe early-onset, drug-resistant epilepsy syndromes.
Originator
Sources: Adams R, Hunt M, Clark JH. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc. 1940;62:196-200. | Mechoulam R, Shvo Y. Hashish. 1. Structure of Cannabidiol. Tetrahedron. 1963;19(12):2073-8
Curator's Comment: Although cannabidiol was isolated from marijuana extract in 1940 by Adams et al., for almost 25 years no further work has been reported, except for a few early works about its isolation. Only in 1963 its exact chemical structure was elucidated by Mechoulam and Shvo. https://www.ncbi.nlm.nih.gov/pubmed/18833429
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16258853 |
|||
Target ID: CHEMBL4794 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11606325 |
3.2 µM [EC50] | ||
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27754480 |
11.0 nM [Ki] | ||
Target ID: CHEMBL1075322 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17876302 |
445.0 nM [IC50] | ||
Target ID: CHEMBL1075092 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22585736 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | SATIVEX Approved UseSativex is used in multiple sclerosis (MS) to improve symptoms related to muscle stiffness. This is also called “spasticity”. Spasticity means there is an increase in ‘muscle tone’ which makes the muscles feel more stiff or rigid. This means it is more difficult than normal to move the muscle. Sativex is used when other medicines have not helped your muscle stiffness. |
|||
Primary | SATIVEX Approved UseSATIVEX® buccal spray is indicated as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain. |
|||
Primary | EPIDIOLEX Approved UseUnknown |
|||
Primary | EPIDIOLEX Approved UseUnknown |
|||
Primary | EPIDIOLEX Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
330.3 ng/mL |
750 mg 2 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
541.2 ng/mL |
1500 mg 2 times / day multiple, oral dose: 1500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
292.4 ng/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
327 ng/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
782 ng/mL |
6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1588 ng/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1745 ng × h/mL |
750 mg 2 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3236 ng × h/mL |
1500 mg 2 times / day multiple, oral dose: 1500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1618 ng × h/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2198 ng × h/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3900 ng × h/mL |
6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8670 ng × h/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
56.41 h |
750 mg 2 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
60.54 h |
1500 mg 2 times / day multiple, oral dose: 1500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
14.43 h |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
15.42 h |
6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6% |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6% |
6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Disc. AE: Transaminases increased... Other AEs: Transaminases increased, Decreased appetite... AEs leading to discontinuation/dose reduction: Transaminases increased (1.3%) Other AEs:Transaminases increased (8%) Sources: Decreased appetite (16%) Diarrhea (9%) Weight decreased (3%) Abdominal discomfort (3%) Somnolence (23%) Sedation (3%) Lethargy (4%) Fatigue (11%) Malaise (11%) Asthenia (11%) Irritability (9%) Agitation (9%) Insomnia (11%) Sleep disorder (11%) Poor quality sleep (11%) Aggression (3%) Anger (3%) Drooling (1%) Salivary hypersecretion (1%) Gait disturbance (3%) Infection viral (7%) Pneumonia (8%) Fungal infection (1%) Infection NOS (25%) Rash (7%) Hypoxia (3%) Respiratory failure (3%) |
20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Disc. AE: Transaminases increased... Other AEs: Transaminases increased, Decreased appetite... AEs leading to discontinuation/dose reduction: Transaminases increased (5.9%) Other AEs:Transaminases increased (16%) Sources: Decreased appetite (22%) Diarrhea (20%) Weight decreased (5%) Abdominal discomfort (3%) Somnolence (25%) Sedation (6%) Lethargy (8%) Fatigue (12%) Malaise (12%) Asthenia (12%) Irritability (5%) Agitation (5%) Aggression (5%) Anger (5%) Drooling (4%) Salivary hypersecretion (4%) Gait disturbance (2%) Infection viral (11%) Pneumonia (5%) Fungal infection (3%) Infection NOS (21%) Rash (13%) Hypoxia (3%) Gastroenteritis (4%) Insomnia (5%) Sleep disorder (5%) Poor quality sleep (5%) Respiratory failure (3%) |
50 mg/kg/day 1 times / day multiple, oral Dose: 50 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 50 mg/kg/day, 1 times / day Sources: |
healthy, adult n = 5 Health Status: healthy Age Group: adult Population Size: 5 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Drooling | 1% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Fungal infection | 1% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Salivary hypersecretion | 1% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Transaminases increased | 1.3% Disc. AE |
10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Asthenia | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Fatigue | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Insomnia | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Malaise | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Poor quality sleep | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Sleep disorder | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Decreased appetite | 16% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Somnolence | 23% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Infection NOS | 25% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Abdominal discomfort | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Aggression | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Anger | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Gait disturbance | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Hypoxia | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Respiratory failure | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Sedation | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Weight decreased | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Lethargy | 4% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Infection viral | 7% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Rash | 7% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Pneumonia | 8% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Transaminases increased | 8% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Agitation | 9% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Diarrhea | 9% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Irritability | 9% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Infection viral | 11% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Asthenia | 12% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Fatigue | 12% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Malaise | 12% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Rash | 13% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Transaminases increased | 16% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Gait disturbance | 2% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Diarrhea | 20% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Infection NOS | 21% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Decreased appetite | 22% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Somnolence | 25% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Abdominal discomfort | 3% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Fungal infection | 3% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Hypoxia | 3% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Respiratory failure | 3% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Drooling | 4% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Gastroenteritis | 4% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Salivary hypersecretion | 4% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Aggression | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Agitation | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Anger | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Insomnia | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Irritability | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Pneumonia | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Poor quality sleep | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Sleep disorder | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Weight decreased | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Transaminases increased | 5.9% Disc. AE |
20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Sedation | 6% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Lethargy | 8% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000PharmR.pdf#page=20 Page: 20.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis and pharmacological evaluation in mice of halogenated cannabidiol derivatives. | 1999 Nov |
|
Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice. | 2001 May |
|
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. | 2001 Oct |
|
Medicinal use of cannabis: history and current status. | 2001 Summer |
|
The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. | 2001 Summer |
|
Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. | 2002 Dec 31 |
|
(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. | 2002 Dec 5 |
|
Cannabinol enhancement of interleukin-2 (IL-2) expression by T cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity. | 2002 Feb |
|
Fully automated determination of cannabinoids in hair samples using headspace solid-phase microextraction and gas chromatography-mass spectrometry. | 2002 Nov-Dec |
|
Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects? | 2003 Dec |
|
Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. | 2003 Dec 12 |
|
Nonpsychotropic cannabinoid receptors regulate microglial cell migration. | 2003 Feb 15 |
|
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. | 2003 Feb 25 |
|
[Weather-induced changes in cannabinoid content of hair]. | 2003 Jan-Feb |
|
Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. | 2003 Jul 31 |
|
Simultaneous detection of some drugs of abuse in saliva samples by SPME technique. | 2003 Jun 24 |
|
G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current. | 2003 Nov 14 |
|
Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. | 2003 Sep |
|
An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. | 2004 Aug |
|
Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. | 2004 Aug |
|
Pain reduction and lack of psychotropic effects with ajulemic acid: comment on the article by Sumariwalla et al. | 2004 Dec |
|
Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. | 2004 Dec |
|
Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. | 2004 Dec |
|
(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. | 2004 Dec 15 |
|
Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. | 2004 Feb |
|
Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). | 2004 Jan |
|
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. | 2004 Mar |
|
6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. | 2004 Mar 8 |
|
NMR assignments of the major cannabinoids and cannabiflavonoids isolated from flowers of Cannabis sativa. | 2004 Nov-Dec |
|
Cannabinoids in hair: strategy to prove marijuana/hashish consumption. | 2004 Oct 29 |
|
Cannabis (marijuana) contamination of United States and foreign paper currency. | 2004 Sep |
|
Gene ancestry of the cannabinoid receptor family. | 2005 Dec |
|
Marijuana extracts possess the effects like the endocrine disrupting chemicals. | 2005 Jan 31 |
|
A rapid and simple procedure for the determination of cannabinoids in hemp food products by gas chromatography-mass spectrometry. | 2005 Jan 4 |
Patents
Sample Use Guides
SATIVEX® is provided as a buccal spray in a 5.5 ml vial, with each 100 microlitre spray providing 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). In patients with multiple sclerosis, the median daily dosage of SATIVEX® in the extension phase of the 4-week clinical trial was 5 sprays per day. The majority of patients required 12 sprays or less; dosage should be adjusted as needed and tolerated. There is limited experience with doses higher than 12 sprays per day. Some patients may require and may tolerate a higher number of sprays. In patients with pain in cancer, the median daily dosage of SATIVEX® was 8 actuations (sprays).
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27932991
in vitro pre-treatment of Human Gingival Mesenchymal Stem Cells with 5 uM Cannabidiol (CBD) can influence their expression profile
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/17/1959
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
471815
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
NCI_THESAURUS |
C274
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
NCI_THESAURUS |
C1742
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
444814
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
860921
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
409313
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
609617
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
DSLD |
3397 (Number of products:162)
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
617417
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
521416
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
WHO-ATC |
N03AX24
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
452614
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
620417
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
696519
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
734820
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
806620
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
545316
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
482315
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
656618
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
736020
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
819221
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
538916
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
WHO-ATC |
N02BG10
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
763820
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
486115
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
610117
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
488315
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
510716
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
628818
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
549616
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
498215
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
668918
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
734620
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
438214
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
860821
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
439414
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
421213
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
FDA ORPHAN DRUG |
450814
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
||
|
NCI_THESAURUS |
C105578
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2045371
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
1089149
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
CHEMBL190461
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
Cannabidiol
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
CD-48
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
SUB26600
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
C118452
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
CANNABIDIOL
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
69478
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
1089161
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
ALTERNATIVE | |||
|
10423
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
DB09061
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
19GBJ60SN5
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
5288
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
19GBJ60SN5
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
13956-29-1
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
644019
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
DTXSID00871959
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
D002185
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | |||
|
M3020
Created by
admin on Sun Dec 18 18:42:38 UTC 2022 , Edited by admin on Sun Dec 18 18:42:38 UTC 2022
|
PRIMARY | Merck Index |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE ACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)